Oral Sildenafil Ameliorates Impaired Pulmonary Circulation Early After Bidirectional Cavopulmonary Shunt

Annals of Thoracic Surgery

Volumn 83, Issue 5, 2007, Pages

  Nemoto, Shintaro ^a   Umehara, Eitaro ^a   Ikeda, Tadashi ^a   Itonaga, Tatsuya ^a   Komeda, Masashi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; NITRIC OXIDE; SILDENAFIL; VASODILATOR AGENT;

ANAMNESIS; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; DRUG DOSE INCREASE; ELECTROCARDIOGRAM; EXTUBATION; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HUMAN; INFANT; LUNG ARTERIOVENOUS SHUNT; LUNG CIRCULATION; LUNG DISEASE; LUNG HEMODYNAMICS; LUNG PRESSURE; NEWBORN PERIOD; OXYGEN SATURATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; HEART BYPASS, RIGHT; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PURINES; SULFONES; VASCULAR DISEASES; VASODILATOR AGENTS;

EID: 34247219668     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.01.065     Document Type: Article

References (20)

1. Gentles T.L., Meyer Jr. J.E., Gauvreau K., et al. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg 114 (1997) 376-391
2. Knott-Craig C.J., Danielson G.K., Schaff H.V., et al. The modified Fontan operation: an analysis of risk factors for early postoperative death and takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg 109 (1995) 1237-1243
3. Schmid E.R., Burki C., Engel M.H., Schmidlin D., Tornic M., and Seifert B. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth Analg 89 (1999) 1108-1115
4. Miyaji K., Nagata N., Miyamoto T., and Kitahori K. Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure. J Thorac Cardiovasc Surg 125 (2003) 437-439
5. Takahashi K., Mori Y., Yamamura H., Nakanishi T., and Nakazawa M. Effects of beraprost sodium on pulmonary vascular resistance in candidate for a Fontan procedure: a preliminary study. Pediatr Int 45 (2003) 671-675
6. Stocker C., Penny D.J., Brizard C.P., Cochrane A.D., Soto R., and Shekerdemian L.S. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 29 (2003) 1996-2003
7. Leuchte H.H., Schwaiblmair M., Baumgartner R.A., Neurohr C.F., Kolbe T., and Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 125 (2004) 580-586
8. Reffelmann T., and Kloner R.A. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108 (2003) 239-244
9. Schlze-Neick I., Hartenstein P., Li J., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108 Suppl II (2003) II-67-II-73
10. Atz A.M., Lefler A.K., Fairbrother D.L., Uber W.E., and Bradley S.M. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisis. J Thorac Cardiovasc Surg 124 (2002) 628-629
11. Atz A.M., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anestheology 91 (1999) 307-310
12. Shekerdemian L.S., Ravn H.B., and Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165 (2002) 1098-1102
13. Nakata S., Imai Y., Takanashi Y., et al. A new method of the quantitative standardization of cross-sectional areas of the pulmonary arteries in congenital heart diseases with decreased pulmonary blood flow. J Thorac Cardiovasc Surg 88 (1984) 610-619
14. Kitamukai O., Sakuma M., Takahashi T., Nawata J., Ikeda J., and Shirato K. Hemodynamic effects of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonary hypertension. Intern Med 41 (2002) 429-434
15. Morita K., Ihnkem K., Buckberg G.D., Sherman M.P., and Ignarro L.J. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann Thorac Surg 61 (1996) 1775-1780
16. Glavind-Kristensen M., Brix-Kristensen V., Toennesen E., et al. Pulmonary endothelial dysfunction after cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiol Scand 46 (2002) 853-859
17. Khambadkone S., Li J., de Leval M.R., Cullen S., Deanfield J.E., and Redington A.N. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107 (2003) 3204-3208
18. Levy M., Danel C., Leval A.M., Leca F., Vouhe P.R., and Israel-Biet D. Nitric oxide synthetase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome?. J Thorac Cardiovasc Surg 125 (2003) 1083-1090
19. Mahle W.T., Todd K., and Fyfe D.A. Endothelial function following the Fontan operation. Am J Cardiol 91 (2003) 1286-1288
20. Atz A.M., Adatia I., and Wessel D.L. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 62 (1996) 1759-1764